Khurshid S, Venkataramany A, Montes M, Kipp J, Roberts R, Wein N
Mol Ther Oncol. 2024; 32(4):200908.
PMID: 39720325
PMC: 11666956.
DOI: 10.1016/j.omton.2024.200908.
Aucouturier C, Soirat N, Castera L, Bertrand D, Atkinson A, Lavole T
BMC Genomics. 2024; 25(1):909.
PMID: 39350015
PMC: 11440762.
DOI: 10.1186/s12864-024-10741-0.
Saadh M, Ehymayed H, Alazzawi T, Fahdil A, Athab Z, Yarmukhamedov B
Cell Biochem Biophys. 2024; 83(1):109-133.
PMID: 39243349
DOI: 10.1007/s12013-024-01492-6.
Bubenik J, Scotti M, Swanson M
Genes Dev. 2024; 38(15-16):698-717.
PMID: 39142832
PMC: 11444190.
DOI: 10.1101/gad.351612.124.
Shimo T, Ueda O, Yamamoto S
PLoS One. 2024; 19(7):e0305012.
PMID: 38980892
PMC: 11232981.
DOI: 10.1371/journal.pone.0305012.
Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy.
Hart C, Lee Y, Xie J, Gao G, Lin B, Hammers D
JCI Insight. 2024; 9(11).
PMID: 38713520
PMC: 11382885.
DOI: 10.1172/jci.insight.165869.
Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications.
Roberts T
Mol Ther Methods Clin Dev. 2023; 31:101160.
PMID: 38074414
PMC: 10709182.
DOI: 10.1016/j.omtm.2023.101160.
RNA-Based Therapeutic Technology.
Mashima R, Takada S, Miyamoto Y
Int J Mol Sci. 2023; 24(20).
PMID: 37894911
PMC: 10607345.
DOI: 10.3390/ijms242015230.
Development of Engineered-U1 snRNA Therapies: Current Status.
Goncalves M, Santos J, Coutinho M, Matos L, Alves S
Int J Mol Sci. 2023; 24(19).
PMID: 37834063
PMC: 10572768.
DOI: 10.3390/ijms241914617.
Therapeutic approaches for Duchenne muscular dystrophy.
Roberts T, Wood M, Davies K
Nat Rev Drug Discov. 2023; 22(11):917-934.
PMID: 37652974
DOI: 10.1038/s41573-023-00775-6.
Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mice.
Saoudi A, Barberat S, Le Coz O, Vacca O, Doisy Caquant M, Tensorer T
Mol Ther Nucleic Acids. 2023; 32:173-188.
PMID: 37078061
PMC: 10106732.
DOI: 10.1016/j.omtn.2023.03.009.
Efficient Modulation of Exon Skipping via Antisense Circular RNAs.
Ren S, Huang M, Bai R, Chen L, Yang J, Zhang J
Research (Wash D C). 2023; 6:0045.
PMID: 37040525
PMC: 10076032.
DOI: 10.34133/research.0045.
Counteracting the Common Shwachman-Diamond Syndrome-Causing c.258+2T>C Mutation by RNA Therapeutics and Base/Prime Editing.
Peretto L, Tonetto E, Maestri I, Bezzerri V, Valli R, Cipolli M
Int J Mol Sci. 2023; 24(4).
PMID: 36835434
PMC: 9962285.
DOI: 10.3390/ijms24044024.
Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle.
Morin A, Stantzou A, Petrova O, Hildyard J, Tensorer T, Matouk M
Proc Natl Acad Sci U S A. 2023; 120(2):e2206324120.
PMID: 36595689
PMC: 9926233.
DOI: 10.1073/pnas.2206324120.
Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics.
Keyt L, Duran J, Bui Q, Chen C, Miyamoto M, Silva Enciso J
Front Cardiovasc Med. 2022; 9:972301.
PMID: 36158814
PMC: 9489950.
DOI: 10.3389/fcvm.2022.972301.
RNA splicing: a dual-edged sword for hepatocellular carcinoma.
Kashyap A, Tripathi G, Tripathi A, Rao R, Kashyap M, Bhat A
Med Oncol. 2022; 39(11):173.
PMID: 35972700
DOI: 10.1007/s12032-022-01726-8.
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse.
Wein N, Vetter T, Vulin A, Simmons T, Frair E, J Bradley A
Mol Ther Methods Clin Dev. 2022; 26:279-293.
PMID: 35949298
PMC: 9356240.
DOI: 10.1016/j.omtm.2022.07.005.
Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy.
Eser G, Topaloglu H
Genes (Basel). 2022; 13(7).
PMID: 35886024
PMC: 9320322.
DOI: 10.3390/genes13071241.
Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription.
Mollard A, Peccate C, Forand A, Chassagne J, Julien L, Meunier P
Sci Rep. 2022; 12(1):9674.
PMID: 35690627
PMC: 9188557.
DOI: 10.1038/s41598-022-13405-9.
Targeted exon skipping of exon 17 as a therapeutic for neurofibromatosis type I.
Leier A, Moore M, Liu H, Daniel M, Hyde A, Messiaen L
Mol Ther Nucleic Acids. 2022; 28:261-278.
PMID: 35433111
PMC: 8983316.
DOI: 10.1016/j.omtn.2022.03.011.